Current Edition

news

Pivotal Clinical Trial Costs Estimated at $19 Million

A new analysis has found it costs an average of $19 million to get new drugs through pivotal clinical trials and onto the market. Researchers at the Institute for Saf...
Continue Reading →
Europe

Human clinical trial of investigational calcification inhibitor generates promising results

Cardiovascular calcification is a major health concern in patients with kidney failure undergoing hemodialysis. A first-time-in-human clinical trial of an investigati...
Continue Reading →
news

New cancer vaccine may tackle HER2-positive tumors

New research shows that a new cancer vaccine may be effective for treating a range of HER2-positive cancers, including the more aggressive HER2-positive breast cancer...
Continue Reading →
Asia Pacific

Blockchain to Combat Type 2 Diabetes Epidemic in India

Genomics pioneer Shivom hopes to transform diagnosis and treatment of a disease that’s pervasive in the country. London, UK - 25 September 2018: A pioneering diabetes...
Continue Reading →
Europe

Catalent Selected to Provide Oral Delivery Systems for GB Sciences’ Proprietary Parkinson’s Disease Therapies

GB Sciences and Catalent tackle the first-ever formulations of APIs containing up to nine cannabinoids and terpenoids for the treatment of Parkinson’s disease. SWINDO...
Continue Reading →
Europe

New inflammatory biomarker predicts elevated thrombosis risk in cancer patients

(Vienna, 26 September 2018) Cancer patients are known to have an increased risk of thrombosis. As part of the CATS study, MedUni Vienna researchers have now investiga...
Continue Reading →
Europe

Psychotropic polypharmacy is common in Alzheimer’s disease

Up to half of people with Alzheimer’s disease (AD) use a psychotropic drug, and one in five uses two or more psychotropics concomitantly, according to a study conduct...
Continue Reading →
Europe

Ryzodeg offers a simpler solution with once-daily dosing and reduced risk of nocturnal hypoglycaemia vs insulin glargine U100 plus insulin aspart

Berlin, Germany, 2 October 2018 ­- When treated with once-daily Ryzodeg®, people with type 2 diabetes achieved similar blood sugar control with half the number of dai...
Continue Reading →
Europe

People with diabetes may achieve improved glycaemic control with Tresiba versus glargine U100, without an increase in hypoglycaemia

Berlin, Germany, 2 October 2018 ­- According to results of a post-hoc analysis people with both type 1 and type 2 diabetes in clinical practice may achieve improved g...
Continue Reading →
Asia Pacific

Addressing social and cultural drivers of type 2 diabetes is key to its treatment and prevention

Berlin, Germany, 2 October 2018 - New research shows healthcare services and public health strategies aimed at reducing the burden of type 2 diabetes may prove ineffe...
Continue Reading →